308 related articles for article (PubMed ID: 27014661)
1. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer.
Phak JH; Kim HJ; Kim WC
Prostate Int; 2016 Mar; 4(1):25-9. PubMed ID: 27014661
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy versus conventionally fractionated external beam radiotherapy for low- and intermediate-risk prostate cancer.
Lee SH; Kim HJ; Kim WC
Asia Pac J Clin Oncol; 2016 Dec; 12(4):388-395. PubMed ID: 27461444
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir.
Anwar M; Weinberg V; Chang AJ; Hsu IC; Roach M; Gottschalk A
Radiat Oncol; 2014 Feb; 9():42. PubMed ID: 24484652
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.
Kim HJ; Phak JH; Kim WC
Prostate Int; 2015 Dec; 3(4):118-22. PubMed ID: 26779457
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Feb; 13(1):21-27. PubMed ID: 26969216
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
[TBL] [Abstract][Full Text] [Related]
7. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.
Davis J; Sharma S; Shumway R; Perry D; Bydder S; Simpson CK; D'Ambrosio D
Cureus; 2015 Dec; 7(12):e395. PubMed ID: 26798571
[TBL] [Abstract][Full Text] [Related]
9. Practical application of biochemical failure definitions: what to do and when to do it.
Kestin LL; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):304-15. PubMed ID: 12023134
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer.
Kim HJ; Phak JH; Kim WC
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e342-e347. PubMed ID: 26846353
[TBL] [Abstract][Full Text] [Related]
11. Long-term results and PSA kinetics after robotic SBRT for prostate cancer: multicenter retrospective study in Korea (Korean radiation oncology group study 15-01).
Park Y; Park HJ; Jang WI; Jeong BK; Kim HJ; Chang AR
Radiat Oncol; 2018 Nov; 13(1):230. PubMed ID: 30470253
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen kinetics following robotic stereotactic body radiotherapy for localized prostate cancer.
Kole TP; Chen LN; Obayomi-Davies O; Kim JS; Lei S; Suy S; Dritschilo A; Collins SP
Acta Oncol; 2015 Jun; 54(6):832-8. PubMed ID: 25467965
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer.
Park YH; Choi IY; Yoon SC; Jang HS; Moon HW; Hong SH; Kim SW; Hwang TK; Lee JY
Prostate Int; 2015 Mar; 3(1):6-9. PubMed ID: 26157760
[TBL] [Abstract][Full Text] [Related]
14. The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancer.
Lin YW; Lin LC; Lin KL
Front Oncol; 2014; 4():278. PubMed ID: 25401085
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806).
Isfahanian N; Lukka H; Dayes I; Quan K; Schnarr KL; Douvi G; Goldberg M; Wright J; Swaminath A; Chow T; Diamond K; Cutz JC; Kavsak P; Thabane L; Tsakiridis T
Clin Genitourin Cancer; 2020 Aug; 18(4):e410-e415. PubMed ID: 32265129
[TBL] [Abstract][Full Text] [Related]
16. High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.
Pontoriero A; Iatì G; Mondello S; Midili F; Siragusa C; Brogna A; Ielo I; Anastasi G; Magno C; Pergolizzi S; De Renzis C
Technol Cancer Res Treat; 2016 Feb; 15(1):179-85. PubMed ID: 25586517
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
[TBL] [Abstract][Full Text] [Related]
18. Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer.
Luo Y; Li M; Qi H; Zhao J; Han Y; Lin Y; Hou Z; Jiang Y
World J Surg Oncol; 2018 Jun; 16(1):107. PubMed ID: 29890979
[TBL] [Abstract][Full Text] [Related]
19. Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?
Kataria S; Koneru H; Guleria S; Danner M; Ayoob M; Yung T; Lei S; Collins BT; Suy S; Lynch JH; Kole T; Collins SP
Front Oncol; 2017; 7():157. PubMed ID: 28791252
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival.
Lee WR; Hanlon AL; Hanks GE
J Urol; 1996 Aug; 156(2 Pt 1):450-3. PubMed ID: 8683700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]